<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the effects of intravenous injection of defibrinogenase on dissoliving dissolve <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and salvaging <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> in <z:hpo ids='HP_0001297'>stroke</z:hpo>-prone <z:hpo ids='HP_0100817'>renovascular hypertension</z:hpo> rats (RHRSP) with middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>(MCAO) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The MCAO in RHRSP was induced by administration in photosensitive dye, <z:chebi fb="0" ids="52261">rose bengal</z:chebi>, and irradiation of the main <z:chebi fb="70" ids="34342">MCA</z:chebi> with a focus laser beam </plain></SENT>
<SENT sid="2" pm="."><plain>The <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in <z:chebi fb="70" ids="34342">MCA</z:chebi> and <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> were examined microscopically in HE stained sections </plain></SENT>
<SENT sid="3" pm="."><plain>Infarction size was determined in triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> stained sections </plain></SENT>
<SENT sid="4" pm="."><plain>Defibrinogenase was injected intravenously at 3, 6, 9, 12 hours and 3, 7 days after MCAO, meanwhile the control group received <z:mpath ids='MPATH_458'>normal</z:mpath> saline </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> rats were killed at 72 hours and evaluated by pathological methods after treatment </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: In the treatment group, the <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were dissolved totally at 3 hours after MCAO, 75% at 6 hours, 13% at 9 hours </plain></SENT>
<SENT sid="7" pm="."><plain>Defibrinogenase failed to dissolve <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> beyond 12 hours after MCAO, just as control group </plain></SENT>
<SENT sid="8" pm="."><plain>In comparison with the control group, defibrinogenase significantly reduced infarction size </plain></SENT>
<SENT sid="9" pm="."><plain>There was no evidence of <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Defibrinogenase can reduce infarction size and dissolve <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> in 6 hours after MCAO without the side effect of <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
</text></document>